Cigna drops US antitrust claims against Celgene over Pomalyst
MLex Summary: Cigna agreed to dismiss its US complaint accusing Celgene of unlawfully extending a monopoly in the market for pomalidomide, a drug used in the treatment of multiple myeloma and...To view the full article, register now.
Already a subscriber? Click here to view full article